Ruhnke Markus, Kofla Grzegorz, Otto Kirsten, Schwartz Stefan
Department of Internal Medicine, Charité Campus Mitte, Berlin, Germany.
CNS Drugs. 2007;21(8):659-76. doi: 10.2165/00023210-200721080-00004.
Early diagnosis of CNS aspergillosis requires a high degree of clinical suspicion, because there are no typical clinical symptoms or CSF findings. Clinical features are usually dramatic and tend to progress rapidly. Changes in mental status, hemiparesis and seizures are most common, but other nonspecific neurological features may occur and should always be an indication for neuroradiological examination in high-risk patients, in order to allow early initiation of antifungal therapy. Low density lesions with little or no mass effect and minimal or no contrast enhancement on CT scans that are usually more numerous on MRI and show intermediate signal intensity within high-signal areas on T2-weighted images, may suggest CNS aspergillosis. Cerebral lesions in CNS aspergillosis are often located not only in the cerebral hemispheres but also in the basal ganglia, thalami, corpus callosum and perforator artery territories. There is frequently a lack of contrast enhancement or perifocal oedema, due to the immunosuppressed status of the patient. A definite diagnosis requires brain tissue for histopathological analysis. However, neurosurgery is often not feasible, so that any of the neuroradiological findings mentioned above should raise the suspicion of CNS aspergillosis in immunocompromised patients and lead to early initiation of antifungal therapy. In the past, amphotericin B-based therapy was the treatment of choice for CNS aspergillosis, but this treatment produced negligible effects. Recently, voriconazole has been reported to be more effective than amphotericin B in the treatment of invasive aspergillosis. Response rates of about 35% have been achieved with voriconazole in patients with CNS aspergillosis. Combination therapy with antifungal agents, such as voriconazole plus caspofungin or liposomal amphotericin B, is being investigated in vitro and in animal models, and optimistic results have been observed. A combined medical and neurosurgical treatment should be considered in all patients with this disease.
中枢神经系统曲霉菌病的早期诊断需要高度的临床怀疑,因为没有典型的临床症状或脑脊液检查结果。临床特征通常较为显著,且往往进展迅速。精神状态改变、偏瘫和癫痫发作最为常见,但也可能出现其他非特异性神经学特征,对于高危患者而言,这些特征始终应作为进行神经影像学检查的指征,以便尽早开始抗真菌治疗。CT扫描显示低密度病变,占位效应小或无占位效应,增强扫描时强化轻微或无强化,这些病变在MRI上通常更多见,在T2加权图像的高信号区域内呈中等信号强度,可能提示中枢神经系统曲霉菌病。中枢神经系统曲霉菌病的脑部病变不仅常位于大脑半球,还见于基底神经节、丘脑、胼胝体和穿支动脉区域。由于患者处于免疫抑制状态,病变通常缺乏强化或灶周水肿。明确诊断需要脑组织进行组织病理学分析。然而,神经外科手术往往不可行,因此上述任何神经影像学表现都应引起对免疫功能低下患者中枢神经系统曲霉菌病的怀疑,并促使尽早开始抗真菌治疗。过去,基于两性霉素B的治疗是中枢神经系统曲霉菌病的首选治疗方法,但这种治疗效果甚微。最近有报道称,伏立康唑在治疗侵袭性曲霉菌病方面比两性霉素B更有效。伏立康唑治疗中枢神经系统曲霉菌病患者的缓解率约为35%。伏立康唑联合卡泊芬净或脂质体两性霉素B等抗真菌药物的联合治疗正在体外和动物模型中进行研究,已观察到乐观的结果。对于所有患有这种疾病的患者,应考虑联合内科和神经外科治疗。